Cargando…
Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and partic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820829/ https://www.ncbi.nlm.nih.gov/pubmed/36614224 http://dx.doi.org/10.3390/ijms24010781 |
_version_ | 1784865554161467392 |
---|---|
author | Makowska, Karolina Nowaczyk, Joanna Blicharz, Leszek Waśkiel-Burnat, Anna Czuwara, Joanna Olszewska, Małgorzata Rudnicka, Lidia |
author_facet | Makowska, Karolina Nowaczyk, Joanna Blicharz, Leszek Waśkiel-Burnat, Anna Czuwara, Joanna Olszewska, Małgorzata Rudnicka, Lidia |
author_sort | Makowska, Karolina |
collection | PubMed |
description | Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease. |
format | Online Article Text |
id | pubmed-9820829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98208292023-01-07 Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments Makowska, Karolina Nowaczyk, Joanna Blicharz, Leszek Waśkiel-Burnat, Anna Czuwara, Joanna Olszewska, Małgorzata Rudnicka, Lidia Int J Mol Sci Review Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease. MDPI 2023-01-02 /pmc/articles/PMC9820829/ /pubmed/36614224 http://dx.doi.org/10.3390/ijms24010781 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Makowska, Karolina Nowaczyk, Joanna Blicharz, Leszek Waśkiel-Burnat, Anna Czuwara, Joanna Olszewska, Małgorzata Rudnicka, Lidia Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title | Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title_full | Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title_fullStr | Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title_full_unstemmed | Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title_short | Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments |
title_sort | immunopathogenesis of atopic dermatitis: focus on interleukins as disease drivers and therapeutic targets for novel treatments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820829/ https://www.ncbi.nlm.nih.gov/pubmed/36614224 http://dx.doi.org/10.3390/ijms24010781 |
work_keys_str_mv | AT makowskakarolina immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT nowaczykjoanna immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT blicharzleszek immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT waskielburnatanna immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT czuwarajoanna immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT olszewskamałgorzata immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments AT rudnickalidia immunopathogenesisofatopicdermatitisfocusoninterleukinsasdiseasedriversandtherapeutictargetsfornoveltreatments |